Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | HRAS | P01112 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10653567 | 0.86 | SIGMAR1 (0.53) | SIGMAR1IDO1 | |
| SCHEMBL5506614 | 0.81 | KDM4E (0.45) | CA2CA1MAPTSIGMAR1CA12 | |
| SCHEMBL8603268 | 0.81 | IDO1 (0.46) | CA2CA1MAPTALOX12ALDH1A1 | |
| SCHEMBL5177626 | 0.81 | IDO1 (0.46) | CA2CA1CA9MAPTGAA | |
| SCHEMBL12805042 | 0.81 | HRAS (0.42) | CA2CA1MAPTGAAALOX12 | |
| SCHEMBL7157405 | 0.79 | PLA2G1B (0.47) | CA2CA1ALDH1A1CA12KMT2A | |
| SCHEMBL5501337 | 0.78 | ALDH1A1 (0.47) | MAPTGAASIGMAR1ALDH1A1HPGD | |
| SCHEMBL14144826 | 0.78 | DRD4 (0.42) | CA2CA1MAPTCA12CA7 | |
| SCHEMBL206646 | 0.77 | HRAS (0.65) | MAPTHRASIDO1MEN1KMT2A | |
| SCHEMBL3043365 | 0.76 | KEAP1 (0.48) | CA2MAPTGAACA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139074-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-05-21 | — | — | US | disclosed |
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20260091123-A1 | COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR OR ATM INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-02 | — | — | US | disclosed |
| EP-4703474-A1 | ANTI-LRRC15 ANTIBODY | Daiichi Sankyo Company, Limited (JP) | 2026-03-04 | — | — | EP | disclosed |
| EP-4696332-A1 | COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE WITH ATR INHIBITOR OR ATM INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2026-02-18 | — | — | EP | disclosed |
| EP-4691497-A1 | COMBINATION OF ANTI-CDH6 ANTIBODY-DRUG CONJUGATE AND HIF-2ALPHA INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-4692351-A1 | ANTI-CD25 ANTIBODY AND ANTI-CD25 ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-12545685-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-12497465-B2 | Combination of antibody-drug conjugate and tubulin inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-12-16 | — | — | US | disclosed |
| CN-102356085-A | Imidazothiazole derivative having proline ring structure | DAIICHI SANKYO CO LTD | 2012-02-15 | — | — | CN | disclosed |
| US-8097622-B2 | Morpholinopurine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-17 | — | — | US | disclosed |
| CN-102245607-A | Morpholinopurine derivative | DAIICHI SANKYO CO LTD | 2011-11-16 | — | — | CN | disclosed |
| EP-2380892-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING PROLINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2341044-A1 | CYCLOALKYLAMINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-07-06 | — | — | EP | disclosed |
| EP-2336132-A1 | MORPHOLINOPURINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
| CN-102066337-A | 5-hydroxypyrimidine-4-carboxamide compounds | DAIICHI SANKYO CO LTD | 2011-05-18 | — | — | CN | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2298778-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING 4,7-DIAZASPIROÝ2.5¨OCTANE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | SIGLEC9, DSG1, VSIG8 | CA2 2024/4885CA1 718/4885CA9 378/4885 |
| US-20260091123-A1 | COMBINATION OF ANTI-B7-H3 ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR OR ATM INHIBITOR | ATR, ATM, ATRIP | CA2 4639/4885CA1 4613/4885CA9 2427/4885 |
| US-12545685-B2 | Dispiropyrrolidine derivatives | TP53, MDM2, TP53BP1 | CA2 3132/4885CA1 2089/4885CA9 3501/4885 |
| US-20260139074-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND TUBULIN INHIBITOR | TUBB6, TUBAL3, TUBB3 | CA2 2632/4885CA1 2302/4885CA9 813/4885 |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | CA2 4189/4885CA1 3870/4885CA9 2569/4885 |
| US-12497465-B2 | Combination of antibody-drug conjugate and tubulin inhibitor | TUBA1C, TUBB1, TUBB | CA2 3417/4885CA1 2390/4885CA9 1426/4885 |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | CA2 3253/4885CA1 3084/4885CA9 3457/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | CA2 1207/4885CA1 961/4885CA9 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.